Jaren Clark

May 11, 2026

As targeted delivery systems grow more biologically complex, antibody format selection is increasingly becoming part of experimental and translational design strategy. Why Researchers Use Fc-Free Formats in Delivery Systems Fab and F(ab')₂ fragments retain the antigen-binding domains of the parent antibody while removing Fc-associated interactions that influence antibody distribution, clearance, and biological behavior. From a targeting standpoint, the fragment preserves specificity for the intended receptor or surface marker. From a mechanistic standpoint, Fc-free formats can alter tissue penetration, biodistribution, and receptor engagement profiles compared with full-length IgG antibodies.4 Fc-free formats reduce or eliminate Fcγ receptor engagement, which is relevant in any workflow where immune cell recruitment or complement activation is not the intended experimental variable. In in vivo environments where immune surveillance is active, full-length IgG antibodies used as targeting ligands may introduce immune-mediated interactions that were never part of the experimental hypothesis. Beyond reducing Fc-mediated interactions, Fc-free formats can offer practical advantages for conjugation workflows. Antibody orientation and surface density are known to influence the targeting behavior of nanoparticle delivery systems, and minimizing Fc exposure may help reduce unintended interactions with Fc receptor–expressing cells. Controlled fragment-based attachment strategies can therefore support more reproducible targeting performance in translational delivery workflows.5 Key idea In targeted delivery workflows, Fc-free fragments can help researchers preserve target engagement while reducing Fc-mediated interactions that may complicate interpretation. The outcome is a targeting format that allows biological results to be attributed more directly to the intended mechanism, rather than requiring researchers to parse contributions from Fc-mediated interactions that were incidental to the study design. Fc-Free Formats in Published Translational Workflows The use of antibody-functionalized constructs in advanced delivery systems is increasingly represented in published translational research, and the role of format in controlling targeting behavior is part of that conversation. Researchers at East China Normal University described an anti-CD3 antibody-modified lipid nanoparticle system designed to selectively engage T cells for in vivo CAR-T cell generation and IL-6 knockdown in leukemia models.1 The system targeted T cells through antibody-mediated engagement, delivering a plasmid encoding both CD19-CAR and IL-6 shRNA. This workflow illustrates how antibody-functionalized LNPs can be designed to direct delivery toward specific immune cell populations, with the antibody component serving as a controlled targeting element rather than an effector molecule. Separately, researchers at the University of Pennsylvania developed antibody-conjugated LNP systems with extrahepatic tropism for in vivo CAR-T cell engineering.2 By conjugating antibodies targeting pan-T cell surface markers to an ionizable LNP platform with inherent splenic tropism, the system delivered CAR mRNA to T cells in vivo, demonstrating antibody- and dose-dependent CAR expression. This work reflects the growing interest in using antibody-guided delivery to direct nucleic acid cargo toward specific cell types with controlled precision. These workflows illustrate that antibody-mediated targeting in advanced delivery systems is an active area of translational development, and that format considerations are embedded in how these systems are designed and interpreted. Format Selection as a Mechanistic Design Choice What these workflows share is an underlying logic: in engineered biological systems, every component of the targeting construct contributes to the observed biology. Antibody format is not a passive choice. When researchers select Fc-free fragments for targeted delivery workflows, they are making a deliberate decision about which biological variables to include and which to remove. That decision shapes what can be measured, what can be attributed, and how confidently results can be interpreted across experimental conditions and model systems. As translational delivery systems become more sophisticated, and as the gap between in vitro observations and in vivo behavior continues to draw scrutiny, the value of intentional format selection becomes clearer. Researchers who account for Fc-mediated interactions as a design variable are better positioned to measure the target, not the noise. Bio X Cell Fab and F(ab')₂ Fragments Bio X Cell Fab and F(ab')₂ fragments are available from catalog clones or customer-provided recombinant sequences for researchers exploring Fc-free formats in mechanistic studies and translational workflows. Fragments are provided in vivo-ready, low-endotoxin, and carrier-free to support reproducible performance across targeted delivery and mechanistic research applications. References 1. Zhou JE, Sun L, Jia Y, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. Journal of Controlled Release. 2022;350:298–307. DOI: 10.1016/j.jconrel.2022.08.033 2. Billingsley MM, Gong N, Mukalel AJ, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20(11):e2304378. DOI: 10.1002/smll.202304378 3. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Advances in Immunology. 2007;96:179–204. DOI: 10.1016/S0065-2776(07)96005-8 4. Xenaki KT, Oliveira S, van Bergen en Henegouwen PMP. Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors. Frontiers in Immunology. 2017;8:1287. DOI: 10.3389/fimmu.2017.01287 5. Brückner M, Simon J, Landfester K, Mailänder V. The conjugation strategy affects antibody orientation and targeting properties of nanocarriers. Nanoscale. 2021;13(21):9816–9824. DOI: 10.1039/D0NR08191D